Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Its crucial to discuss any concerns with your healthcare provider
accessdata.fda.gov Novo Nordisk
Third-Party Testing Independent laboratory analysis of a product by a company with no financial interest in the results
More about compounding concerns An open letter from Eli Lilly and Company regarding certain practices related to Mounjaro and Zepbound (June 2024) FDA warns about adverse events from compounded semaglutide (May 2023) Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs (May 2024) The Center for Medicine in the Public Interest's September 2025 handout explains concerns about mass compounding
US$ 27.34
US$ 28.11
US$ 21.25
